financetom
MARX
financetom
/
Financials
/
MARX
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Mars Acquisition Corp.MARX
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Mars Acquisition Corp. does not have significant operations.

It focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses.

It intends to focus on opportunities in cryptocurrency and blockchain, automobiles, healthcare, financial technology, cyber security, cleantech, software, Internet and artificial intelligence, specialty manufacturing, and other related technology innovations market.

Mars Acquisition Corp. was incorporated in 2021 and is based in New York, New York.

Latest News >
Teleflex's Q2 Adjusted Earnings, Revenue Rise
Teleflex's Q2 Adjusted Earnings, Revenue Rise
Aug 1, 2024
08:48 AM EDT, 08/01/2024 (MT Newswires) -- Teleflex ( TFX ) reported Q2 adjusted earnings Thursday of $3.42 per diluted share, compared with $3.41 a year earlier. Analysts surveyed by Capital IQ expected $3.33. Revenue for the quarter ended June 30 was $749.7 million, compared with $743.3 million a year earlier. Analysts surveyed by Capital IQ expected $763 million. The...
Crocs' Q2 Adjusted Earnings, Revenue Rise; Issues Downside Q3 EPS Outlook; Raises 2024 EPS Guidance
Crocs' Q2 Adjusted Earnings, Revenue Rise; Issues Downside Q3 EPS Outlook; Raises 2024 EPS Guidance
Aug 1, 2024
08:49 AM EDT, 08/01/2024 (MT Newswires) -- Crocs ( CROX ) reported Q2 adjusted earnings Thursday of $4.01 per diluted share, up from $3.59 a year earlier. Analysts polled by Capital IQ expected $3.57. Revenue for the quarter ended June 30 was $1.11 billion, up from $1.07 billion a year earlier. Analysts surveyed by Capital IQ expected $1.10 billion. For...
Regeneron beats quarterly results on strong demand for eczema, eye treatments
Regeneron beats quarterly results on strong demand for eczema, eye treatments
Aug 1, 2024
(Reuters) - Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs. U.S. sales of Eylea, jointly...
APi Group Q2 Adjusted Earnings Up, Net Revenue Down; Issues Q3 Net Revenue Outlook; Maintains 2024 Net Revenue Guidance
APi Group Q2 Adjusted Earnings Up, Net Revenue Down; Issues Q3 Net Revenue Outlook; Maintains 2024 Net Revenue Guidance
Aug 1, 2024
08:46 AM EDT, 08/01/2024 (MT Newswires) -- APi Group ( APG ) reported Q2 adjusted earnings Thursday of $0.49 per diluted share, up from $0.41 a year earlier. Analysts polled by Capital IQ expected $0.47. Net revenue for the quarter ended June 30 was $1.73 billion, down from $1.77 billion a year earlier. Analysts surveyed by Capital IQ expected $1.79...
Copyright 2023-2026 - www.financetom.com All Rights Reserved